Relative miRNA levels at start (T1) and after six months of anti-TNFα/DMARDs combination therapy (T2) in the validation cohort (n = 85). To validate the PCR array data, ten miRNAs differentially expressed were selected (hsa-miR-125b, hsa-miR-23a-3p, hsa-miR-21-5p, hsa-miR-126-3p, hsa-miR-146a-5p, hsa-let-7a-5p, hsa-miR-16-5p, hsa-miR-124a-3p, hsa-miR-155-5p, and hsa-miR-223). (A) Relative expression levels of each miRNA are shown. Boxes indicate the interval between the 25th and 75th percentiles and horizontal bars inside boxes indicate median. Whiskers indicate the interval of data within 1.5 × interquartile ranges (IQR). Closed circles indicate data points outside 1.5 x IQR. *
P <0.05. (B) Comparison of relative change of miRNA levels between responders and non-responders groups for the six miRNAs found significantly altered after therapy in the validation cohort.*
P <0.05. DMARDs, disease-modifying antirheumatic drugs; miRNAs, microRNAs; TNFα, tumor necrosis factor alpha.